secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0000950170-25-033068
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd reports PEMGARDA neutralizes dominant SARS-CoV-2 variant LP.8.1
-----------------------------------------------------------------------

- New in vitro data show PEMGARDA (pemivibart) neutralizes dominant LP.8.1 variant, consistent with prior variants.
- CDC reports LP.8.1, XEC, and KP.3.1.1 make up majority of U.S. cases; all susceptible to PEMGARDA.
- Pemivibart activity remains within expected assay variability range since Omicron BA.2.
- Data provided to U.S. FDA; update to PEMGARDA Fact Sheet for Healthcare Providers anticipated.
- VYD2311, next-gen mAb candidate, also demonstrates neutralizing activity against LP.8.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025033068/0000950170-25-033068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025033068/ivvd-20250305.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-033068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer